Publications by authors named "Grant Sellar"

Claim this Profile
E
Evaluation of the dual mTOR/PI3K inhibitors Gedatolisib (PF-05212384) and PF-04691502 against ovarian cancer xenograft models.
Simon P Langdon, Charlene Kay, In Hwa Um, Michael Dodds, Morwenna Muir, Grant Sellar

Sci Rep· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative gene expression profiling identifies common molecular signatures of NF-κB activation in canine and human diffuse large B cell lymphoma (DLBCL).
Manikhandan A V Mudaliar, Ross D Haggart, Gino Miele, Grant Sellar, Karen A L Tan

PLoS One· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer.
Steven D Heys, Keith N Stewart, Emma J McKenzie, Iain D Miller, Simon Y C Wong, Grant Sellar

Breast Cancer Res Treat· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stoichiometric quantification of Akt phosphorylation using LC-MS/MS.
Abdelmadjid Atrih, Dan Turnock, Grant Sellar, Alastair Thompson, Giora Feuerstein

J Proteome Res· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of ovarian tumour suppressor OPCML in the female CD-1 mouse reproductive tract.
Jean S Fleming, H James McQuillan, Melanie J Millier, Grant C Sellar

Reproduction· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation.
Yan Cui, Ying Ying, Andrew van Hasselt, Ka Man Ng, Jun Yu, Grant C Sellar

PLoS One· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opportunities posed by novel patient selection biomarker approaches in oncology drug development: going beyond the cytotoxics.
Grant Sellar, John D Alvarez, Frank Loganzo, Richat Abbas, Fred Immermann

Biomark Med· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The IgLON family in epithelial ovarian cancer: expression profiles and clinicopathologic correlates.
Evangelos Ntougkos, Robert Rush, Diane Scott, Tobias Frankenberg, Hani Gabra, Grant C Sellar

Clin Cancer Res· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chx10 repression of Mitf is required for the maintenance of mammalian neuroretinal identity.
D Jonathan Horsford, Minh-Thanh T Nguyen, Grant C Sellar, Rashmi Kothary, Heinz Arnheiter

Development· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression.
Euan A Stronach, Grant C Sellar, Cherie Blenkiron, Genevieve J Rabiasz, Karen J Taylor

Cancer Res· December 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer.
Grant C Sellar, Karen P Watt, Genevieve J Rabiasz, Euan A Stronach, Li Li

Nat Genet· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer.
Grant C Sellar, Karen P Watt, Li Li, Barry D Nelkin, Genevieve J Rabiasz

Int J Oncol· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: correlation with clinical outcome and tumor clinicopathological parameters.
Michael D Oberst, Michael D Johnson, Robert B Dickson, Chen-Yong Lin, Baljit Singh, Grant C Sellar

Clin Cancer Res· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis